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cost of each stage of kidney disease according scheduled visits in each condition, 
and, therefore, to calculate the economic burden of one year dialysis for the Spanish 
Health System, to check the advantage of a treatment that could delay the disease 
progression of ADPKD. Methods: The model was based in normal practice of a 
specific hospital, selected for it’s expertise within ADPKD. To build the model the 
following figures were provided: Hospital costs (number of expected healthcare 
provider visits, analytics, image diagnosis), and other expected costs (such ambu-
lance transport and concomitant treatments for hypertension, hypercholester-
olemia, hyperuricemia, pain, infections, and haematuria). In addition to this, costs 
from the patient’s perspective, namely medication and transport costs were also 
analysed. Results: The annual cost for dialysis patients in Hospital La Paz, and 
Madrid Province, in general, is 56,028 euros (43,980.00 € for Hospital costs, up to 600 
€ for medication, and 11,448 € for ambulance transport) , while the rest of Chronic 
Kidney Disease stages (CKD stages 1-4) range annually between 809-1.551 € (Hospital 
costs and medication). Therefore, avoiding 1 year of dialysis will represent around 
54,800 € savings. ADPKD patients cover additional expenses (up to 350 € for medi-
cation and 8-195 € for transport, annually). ConClusions: Dialysis extensively 
increases the economic burden of ADPKD, this is mainly seen in the healthcare 
system. ADPKD patients are faced with medication costs and travel expenses, as 
well as other incommodities and non-calculated indirect costs. Therefore, a treat-
ment able to delay the disease progression represents an important step towards 
patient wellbeing and big savings for the Health System
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objeCtives: The cross sectional study aims to estimate the impact of socio-
economic determinants, such as education and employment status, on the social 
cost of a patient with chronic kidney disease (CKD) stage IV and V pre-dialyses in 
Italy Methods: Individual socio-economic and clinical data have been collected 
for all adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region 
during 7 weeks between 2012 and 2013. Direct medical costs have been estimated 
using tariff for laboratory test, diagnostic exams, visits and hospitalization and 
price for drugs. The cost of diet, patients and caregivers travel expenses, formal and 
informal care have been evaluated as direct non medical costs. The human capital 
approach has been used for estimating the loss of productivity of patients and 
caregivers. The incremental effects of socio-economic determinants on social cost 
of CKD were estimated by multivariate Generalized Linear Models (log link, Gamma 
family) adjusting for gender, age and stage of disease. Results: No qualification 
and low levels of educations and non-working status characterized, respectively, 
the 54% and 89% of 484 patients enrolled. The raw estimated mean annual social 
costs were € 9,855 (± € 6,826) per patient with CKD. Direct medical costs amounted 
to € 4,352 (± 4,071), representing the 44% of the overall cost, while direct non medi-
cal costs and indirect costs accounted for 30% and 26% (€ 2.912 ± € 3,823 and € 2,590 
± € 3,210). The incremental effect of non-working status on direct medical cost 
was € 1.321 (95% CI: 121-2.520, p< 0,05). Employment condition and high levels of 
education had an incremental effect on indirect costs of € 2.616 (95% CI: 391-4.841, 
p< 0,05) and € 1.039 (95% CI: 135-1.943, p< 0,05). ConClusions: Socio-economic 
inequalities lead to a significant increase of direct medical cost of CKD. High edu-
cation and employment status of patients significantly increase the indirect cost 
component of CKD social cost.
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bACkgRound: Overactive bladder (OAB) symptoms still are not treated in Russian 
Federation in most cases though several medicines are available at the pharmaceuti-
cal market. Direct and indirect costs associated with treatment are important for 
decision makers in health care. objeCtives: To conduct cost analysis of solifenacin 
for OAB symptoms vs absence of pharmacotherapy from the Russian government 
perspective. Methods: A mathematical model was constructed to calculate direct 
and indirect costs associated with OAB for 1 year. Direct medical costs included 
OAB treatment with solifenacin when relevant, urine pads, treatment of compli-
cations and concomitant conditions (CCC) such as urinary infections, skin rash, 
depression and fractures. Indirect costs included productivity losses in patients 
of working ages. Data on incidence of CCC for solifenacin treatment and no treat-
ment strategies was derived from clinical studies. One-way sensitivity analysis was 
performed. Results: Direct medical costs are higher for soilifenacin strategy vs 
no treatment: € 567 and € 483 respectively with cost difference of € 84 per patient per 
year. But solifenacin appears to be cost saving strategy vs no treatment when total 
costs are taken into account: cost difference is € 40 per patient per year in favor of 
solifenacin. Solifenacin remains cost-saving option until the cost of urinary pads 
decreases twice from baseline or the solifenacin efficacy becomes less for 15% from 
baseline. ConClusions: Solifenacin seems to be an acceptable option for Russian 
healthcare from the government perspective.
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prescribed significantly higher number of drugs compared to those without diabetes 
and age ≤ 50 years. The top three prescribed medication groups were antianemic 
preparations (B03), minerals (A12) and vitamins (A11). Vitamin D analogues were 
prescribed to 31.3% of the patients. The predominantly prescribed vitamin D analogue 
was calcitriol. Around 91% of the patients were prescribed phosphate binders (PB). 
Calcium carbonate (88.8%) was the most commonly prescribed phosphate binder, 
whereas sevelamer and lanthanum were seldom prescribed. None of the patients 
was prescribed calcium acetate and aluminum-based PB. ConClusions: Patients 
with CKD stage 5D are prescribed higher number and variety of drugs for the man-
agement of comorbidities associated with kidney disease. Although non-calcium/
non-aluminum based PB have less side effects as compared to calcium-based PB, 
they are seldom prescribed.
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objeCtives: Chronic kidney disease (CKD) is one of the most commonly occurring 
non-communicable diseases in India. CKD is associated with significant morbidity, 
mortality and economic burden in India. The objective of the present study is to 
estimate the prevalence of CKD in India. Methods: A systemic search of published 
literature was carried out using PubMed, Elsevier ScienceDirect, Cochrane library 
databases and Google scholar (from 1990 to April 2015) by two independent review-
ers. Reference list of the related articles was also screened to find out the relevant 
studies. CKD definition of KDIGO guideline was used for inclusion criteria. Cochrane 
Q-statistics test and I2 statistics were used to assess the heterogeneity. Random 
effect model was used. Comprehensive Meta-Analysis software (Version 2.2, Biostat, 
Englewood NJ) was used. Results: Five studies were selected as per inclusion crite-
ria. These studies covered the different geographical regions in India. The numbers 
of participants ranged from 2091 to 5588. Pooled rate estimates suggest that 56.11% 
(95% CI, 48.46-63.75) of the patients were male. Hypertension and diabetes were 
found to be the most common comorbidities according to overall pooled estimates 
[48.67 (95% CI, 19.30-78.05) and 17.39 (95% CI, 6.67-28.12), respectively]. Modification 
of Diet in Renal Disease (MDRD) formula for GFR calculation was used by all studies. 
According to MDRD, CKD pooled prevalence in people over 18 years was found to be 
2.97% (95% confidence interval [CI], 1.38%-4.56%). However, Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula was used by two studies and pooled 
prevalence found to be 3.51%. Overall prevalence of end stage renal disease (ESRD) 
was 0.27% (95% CI, 0.06%-0.48%). Pooled estimate for the prevalence of protein urea 
was 6.98% (95% CI, 2.04%-11.91%). ConClusions: The prevalence of CKD, according 
to MDRD and CKD-EPI was 3% and 4%, respectively. Hypertension was found to be 
most commonly occurring co-morbidity (49%). About 7% of the Indian patients were 
found to have proteinuria.
Urinary/KiDney DiSorDerS – cost Studies
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objeCtives: Our goal was to analyze the rising utilization and to provide a com-
parison between expected number of patients and expenditures described in the 
submitted budget impact analysis and the real expenditures of mirabegron for 
treatment of overactive bladder since its introduction in the Czech Republic in 
January 2014. Methods: The data source for our analysis was the business activ-
ity monitoring database of the General Health Insurance Company of the Czech 
Republic (VZP CR). VZP CR covers approximately 60 % of marketshare in the Czech 
Republic. Patient was defined as an insured person with a recorded prescription 
for mirabegron (G04BD12) during the observed period 01-12/2014. We identified 
the number of patients treated with mirabegron in the observed period and deter-
mined the real expenditures. We compared the real data with submitted BIA predic-
tions. Results: Since the introduction of mirabegron in January 2014 its utilization 
rose to 1.870 million DDD till 12/2014. There were 11 437 patients treated with mira-
begron and the real expenditures of VZP CR representing 60% were € 2.6 million 
(1EUR= 27,24CZK) in 2014, which strongly differed from the predicted number of 
patients (2026) and expenditures (€ 672t-€ 1.mil) presented in the base case budget 
impact analysis in the reimbursement decision published by State Institute of Drug 
Control (SUKL). ConClusions: There was a significant difference between expen-
ditures predicted in the submitted budget impact analysis and real expenditures. 
The real expenditures were almost 4 times higher than the base case predictions 
(2,5x higher when calculated with cost per patient estimation by SUKL) and more 
than 30% higher than the upper predictions for the first year. Expenditures in the 
first quarter 2015 (€ 1,5 million) have already reached the predictions for the whole 
2015 according the base case. Further analysis will follow to confirm this trend.
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objeCtives: Autosomal Dominant Polycystic Kidney Disease (ADPKD) imposes a 
significant economic burden on healthcare systems, particularly in advanced stages 
(5 or End Stage Renal Disease, ESRD). The aim of this model is to study the usual 
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objeCtives: The health and economic burden of Hepatitis C virus (HCV) infection 
in chronic kidney disease (CKD) patients in the United States is significant. GZR 
(NS3/4A protease inhibitor)/EBR (NS5A inhibitor) have been shown to be highly effec-
tive and well tolerated in HCV G1 patients with advanced CKD. Our objective was to 
project the clinical and economic impact of GZR/EBR compared with no treatment 
(NoTx) and pegylated interferon plus ribavirin (peg-IFN/RBV). Methods: A state-
transition model of chronic HCV, liver disease, and CKD was developed to project 
lifetime incidence of liver complications, including hepatocellular carcinoma (HCC), 
life expectancy, discounted quality-adjusted life years (QALY), and discounted dis-
ease cost (COST) (2015 US dollars). Efficacy of GZR/EBR was obtained from C-SURFER, 
a phase 2/3, randomized, double-blind, placebo-controlled trial of GZR/EBR in HCV 
G1 patients in CKD stages 4/5. In the pre-specified primary population, the propor-
tion of patients achieving sustained viral response 12 weeks after the completion 
of therapy was 0.99 (0.95–1.00). Based on the results of a meta-analysis, we assumed 
an efficacy of 0.60 (0.47–0.71) for peg-IFN/RBV. Data on baseline characteristics of the 
simulated patients were obtained from NHANES. Natural history parameters were 
estimated from published studies. Drawing parameter values from well-defined 
statistical distributions, one-thousand Monte Carlo simulations were conducted 
to estimate mean incidence and 95% uncertainty intervals. Results: Incidence of 
HCC was 1.11% (0.05–4.61) with GZR/EBR compared with 23.20% (8.79–42.30) when 
NoTx was used and 9.83% (2.85–21.26) with peg-IFN/RBV. Compared with NoTx 
and peg-IFN/RBV, GZR/EBR increased QALYs by 2.38 (1.62–3.30) and 1.41 (0.76–2.22) 
years, respectively. COST of $138,304 (122,047–155,296) was lowest with GZR/EBR. 
In comparison, Peg-IFN/RBV’s COST was $144,562 (126,553–165,999) and COST with 
NoTx was $162,846 (141,624–187,487). ConClusions: Our model predicts that GZR/
EBR will reduce the incidence of liver-related complications and disease costs and 
prolong QALYs in patients with HCV G1 infection and CKD.
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objeCtives: To explore the cost-effectiveness of bacterial whole-genome sequenc-
ing (bWGS) in determining antibiotic resistance and selecting antibiotics for treat-
ment of urinary-tract infections (UTI), from the perspective of the UK National 
Health Service. Methods: A decision-tree model was developed to compare the 
cost-effectiveness of UTI treatment with or without bWGS. Nitrofurantoin (NTF), tri-
methoprim and co-amoxiclav were designated as first-, second- and last-line treat-
ments respectively, in accordance with treatment guidelines. Parameters extracted 
from peer-reviewed literature included the prevalence of resistance and disease-state 
utilities. Duration and cost of treatments were taken from the British National 
Formulary. The cost and time to perform bWGS for a complete E. coli genome using 
the MiSeq platform were estimated. The incremental cost-effectiveness ratio was 
calculated as cost (GBP) per quality-adjusted life-year (QALY). Threshold analyses 
were performed to explore scenarios where bWGS could become a cost-effective 
strategy. Results: Using a current prevalence of resistance to NTF of 5.3% and a cost 
per genome of £39.69, bWGS was dominated; being more expensive and with worse 
health outcomes than current clinical practice. However, an ~80% reduction in cost 
of sequencing would lead to bWGS being cost-saving compared to current practice. 
Alternatively, if NTF resistance prevalence increased to 44%, bWGS could become cost-
effective at £20,000/QALY. Under some scenarios, such as a reduced bWGS cost of £15 
per genome and increased NTF resistance prevalence of 25%, bWGS would become 
a dominant strategy; being less expensive with better health outcomes than current 
practice. ConClusions: Currently bWGS is not likely to be a cost-effective option for 
directing the selection of antibiotics in the treatment of UTIs; however, in the probable 
situation that the cost of sequencing decreases and resistance to first line antibiot-
ics increases, bWGS is expected to become a cost-effective or dominant option. This 
technology therefore has great potential for improving antibiotic stewardship.
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objeCtives: To assess the cost-effectiveness of mirabegron compared with anti-
muscarinic agents: tolterodine, solifenacin and fesoterodine, in patients with 
overactive bladder (OAB) symptoms from a Spanish National Health Service (NHS) 
perspective. Methods: A Markov model was developed to simulate the course and 
disease management, as well as the adverse effects of treatment, in OAB patients 
over a period of 5 years. Direct health care costs (€ , cost year 2015) included drug 
acquisition, primary care physician and specialist physician visits, incontinence 
pads, surgical procedures, adverse effects of treatment and botox injectionswere 
obtained from Spanish sources. Relative effectiveness estimates of mirabegron 
50mg vs tolterodine , fesoterodine, solifenacin 5 and 10mg were obtained from a 
network meta-analysis, using a calibration method. Effectiveness was measured as 
quality-adjusted life-years (QALYs) gained. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: Mirabegron 50mg/day was associated 
with a gain of 0.01259 QALYs at an additional cost of € 194 per patient vs tolterodine 
objeCtives: To carry out a cost and consequences analysis (CCA) of treating 
Overactive Bladder (OAB) with two flexible-dose of Fesoterodine in routine medi-
cal practice in Spain, from the perspective of the Spanish National Health System 
(NHS). Methods: The CCA was populated with data from an observational, ret-
rospective and multicenter study including OAB patients, both genders, aged 18+ 
years-old managed under routine medical practice conditions of care. OAB patients 
initiating flexible-dose of Fesoterodine were included in two groups according with 
the flexible posology prescribed: escalating from 4-to-8mg (escalating group) or 
initiating and maintaining 8mg (maintaining group). Consequences included a 
health outcomes profile from the patient perspective and the clinician judgment. 
Costs were estimated from healthcare resources utilization only and used year 
2015 unitary prices. The patient outcomes measures included symptoms severity 
and specific quality-of-life by using the OAB-q questionnaire, Patient Perception 
Bladder Condition (PPBC), Patient Perception Urgency Scale (PPUS), and Treatment 
Benefit Scale (TBS). Clinician judgment was approached by the Clinical Global 
Impression (CGI) scale. General linear models, logistic and ordinal regression 
adjusting by covariates were applied. Results: A total of 350 (156 in maintain-
ing group and 194 in escalating) symptomatic OAB patients were extracted from 
the study to populate the CCA. Adjusted healthcare total costs were not statisti-
cally different; € 50.6 (CI:157.4-55.1), p= 0.361. However, patient-reported-outcomes 
were significantly better in the maintaining group than in the escalating; OAB-q 
symptoms (22.6 vs. 26.8, p= 0.015), HRQoL (74.5 vs. 71.1, p= 0.053), less patients 
with urinary incontinence (29.5% vs. 46.4%, OR= 0.4 (CI:0.3-0.7), p= 0.001, and bet-
ter perception or urgency OR= 1.8 (CI:1.2-2.8), p= 0.008. ConClusions: Despite 
the study design, this cost-consequences analysis found that initiating 8mg dose 
of fesoterodine was associated with similar healthcare costs but better patient 
outcomes than escalating from 4mg in the treatment of Overactive Bladder in 
routine medical practice.
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objeCtives: The use of low-osmolar contrast media has reduced the frequency of 
Contrast-Induced Nephropathy (CIN), however, it still exists. As no data are avail-
able in France, a study was set up to estimate the hospital burden associated to this 
complication in terms of medical resource used and hospital costs. Methods: 
A retrospective, observational study was conducted using the French exhaustive 
hospital discharge database (PMSI). Stays with an interventional radiology or car-
diology procedure involving the use of a contrast media were identified in 2012 and 
2013 in adults. CIN was defined as the occurrence over the stay of a nephropathy 
CIM-10 code or unscheduled dialysis procedure. Patients’ characteristics and stays 
were described, as well as associated costs. Results: In 2012 and 2013, 1,047,329 
stays were identified with an interventional procedure. Patients were mainly men 
(68.0%) with a mean age of 66.1±13.8. Among those patients, 25.8% were diabetics, 
9.2% had Chronic Kidney Disease (CKD), 3.4% were suffering from heart failure 
and 0.2% had a cardiogenic shock. Overall CIN rate was 3.1%. CIN resulted in an 
extra length of stay (LOS) of 15.8 days (20.5 vs 4.7 days, p< 0.0001) and an extra cost 
of € 12,413 (€ 15,765 vs€ 3,352, p< 0.0001). This result was very similar in each sub-
group analysis (extra cost of € 11,030 for diabetics, € 11,437 for CKD and € 7,257 for 
patients with heart failure). In France, the hospital cost of CIN reached a total cost 
€ 401,023,050 in 2012 and 2013, making it € 200,511,525 per year. ConClusions: 
This study shows that CIN was associated with significant hospital costs due 
to increased LOS, even more when dialysis occurred. The hospital cost of CIN 
could partially cut down through better preventing measures including safer 
media use.
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objeCtives: To assess the cost-effectiveness of a fixed-dose combination (FDC) 
of solifenacin 6 mg/day plus an oral controlled absorption system formulation of 
tamsulosin (TOCAS 0.4 mg/day) compared to tolterodine ER 4 mg/day concomi-
tantly given with tamsulosin 0.4 mg/day in men with lower urinary tract symptoms 
(LUTS) associated with benign prostatic hyperplasia (BPH) in Spain. Methods: A 
Markov model with a 4-week cycle period was developed for men aged ≥ 45 years 
with LUTS/BPH who have moderate-to-severe storage and voiding symptoms. The 
model estimated cost effectiveness over an analytical time horizon of 1 year from 
the perspective of the Spanish National Health System (NHS). Direct health care 
costs (drug acquisition, primary care physician visits and surgical procedures) 
were considered. The effectiveness of treatments was measured using quality-
adjusted life-years (QALYs) gained. Utility values were derived from EQ-5D data 
collected in a randomized controlled trial. Other model inputs were derived from 
the literature or clinical expert opinion. Deterministic and probabilistic sensitivity 
analyses (SA) were undertaken. Results: The FDC of solifenacin 6 mg plus TOCAS 
0.4 mg was associated with a gain of 0.003 QALYs at an additional cost of € 25 per 
patient. The resulting incremental cost effectiveness ratio (ICER) was € 8,471 per 
QALY gained. Time horizon, discontinuation or withdrawal rates and utility values 
were the main drivers of cost-effectiveness. The probability of FDC solifenacin 6 
mg plus TOCAS being cost-effective relative to tolterodine plus tamsulosin was 
97.3% at a willingness to pay threshold of € 30,000 per QALY. ConClusions: The 
FDC of solifenacin 6 mg plus TOCAS is a cost-effective treatment strategy com-
pared with tolterodine plus tamsulosin for men with storage and voiding LUTS/
BPH in the Spanish NHS.
